Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Dec 2016
At a glance
- Drugs Fampridine (Primary)
- Indications Myelitis
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 20 Dec 2016 Planned End Date changed from 1 Jun 2016 to 1 May 2017.
- 24 Feb 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.